A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9)

Over the past few decades, advances in immunological knowledge have led to the identification of novel immune checkpoints, reinvigorating cancer immunotherapy. Immunotherapy, represented by immune checkpoint inhibitors, has become the leader in the precision treatment of cancer, bringing a new dawn...

Descripción completa

Detalles Bibliográficos
Autores principales: Lv, Yan, Ma, Xiao, Ma, Yuxin, Du, Yuxin, Feng, Jifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chongqing Medical University 2022
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404877/
https://www.ncbi.nlm.nih.gov/pubmed/37554219
http://dx.doi.org/10.1016/j.gendis.2022.05.020

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10404877/
https://www.ncbi.nlm.nih.gov/pubmed/37554219
http://dx.doi.org/10.1016/j.gendis.2022.05.020

Ejemplares similares